Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
CONTEXT: First-phase insulin secretion (within 10 min after a sudden rise in plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin mimetic exenatide has glucoregulatory activities in DM2, including glucose-dependent enhancement of insulin secretion. OBJECTIVE: The objective of the study was to determine whether exenatide can restore a more normal pattern of insulin secretion in subjects with DM2. DESIGN: Fasted subjects received iv insulin infusion to reach plasma glucose 4.4-5.6 mmol/liter. Subjects received iv exenatide (DM2) or saline (DM2 and healthy volunteers), followed by iv glucose challenge. PATIENTS: Thirteen evaluable DM2 subjects were included in the study: 11 males, two females; age, 56 +/- 7 yr; body mass index, 31.7 +/- 2.4 kg/m2; hemoglobin A1c, 6.6 +/- 0.7% (mean +/- sd) treated with diet/exercise (n = 1), metformin (n = 10), or acarbose (n = 2). Controls included 12 healthy, weight-matched subjects with normal glucose tolerance: nine males, three females; age, 57 +/- 9 yr; and body mass index, 32.0 +/- 3.0 kg/m2. SETTING: The study was conducted at an academic hospital. MAIN OUTCOME MEASURES: Plasma insulin, plasma C-peptide, insulin secretion rate (derived by deconvolution), and plasma glucagon were the main outcome measures. RESULTS: DM2 subjects administered saline had diminished first-phase insulin secretion, compared with healthy control subjects. Exenatide-treated DM2 subjects had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge, in contrast to saline-treated DM2 subjects. In exenatide-treated DM2 subjects, the most common adverse event was moderate nausea (two of 13 subjects). CONCLUSIONS: Short-term exposure to exenatide can restore the insulin secretory pattern in response to acute rises in glucose concentrations in DM2 patients who, in the absence of exenatide, do not display a first phase of insulin secretion. Loss of first-phase insulin secretion in DM2 patients may be restored by treatment with exenatide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [71]
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · cited 2×
“Diabetes duration (yr) 4 2 NA Diabetes treatment [n (%)] -Glucosidase inhibitors 2 (15) NA Metformin 10 (77) NA Diet/exercise 1 (7) NA”
BackgroundSelf-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Self-citationSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
Self-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605 · cited 1×
“Insulin, Cpeptide, and glucagon were determined by specific immunoassays as previously described (28, 29).”
MethodSelf-citation
Cited by
Items 201–296 of 296
Muskiet, M. H. A., Emanuel, A. L., Smits, M. M., Tonneijck, L., Meijer, R. I., Joles, J. A., Serné, E. H., & van Raalte, D. H. (2019) · Microcirculation · doi:10.1111/micc.12580 · Cited by 11
Exercise Mimetics in Aging: Suggestions from a Systematic Review
Giacomello, E., Nicoletti, C., Canato, M., & Toniolo, L. (2025) · Nutrients · doi:10.3390/nu17060969 · Cited by 10
“Zhang and collaborators reported that the GLP-1 analogue (Val8)GLP-1-glu-PAL reduced motor impairment, dopamine production, and pro-apoptotic signaling in substantia nigra [128].”
Kim, M.-K., Cho, J., Lee, J.-J., Cheong, Y.-H., Son, M.-H., & Lee, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073340 · Cited by 11
“blood glucose levels by stimulating insulin secretion [10],”
BackgroundAnderson, J. E., Gavin, J. R., Kruger, D. F., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0020 · Cited by 10
Partnering with Patients to Improve Therapeutic Outcomes: Incretin-Based Therapy for Type 2 Diabetes
Nadeau, D. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2137 · Cited by 9
Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs
Efendić, S., Alvarsson, M., Brismar, K., & Wagner, H. (2007) · Acta Physiologica · doi:10.1111/j.1748-1716.2007.01789.x · Cited by 10
aThe characteristics of glucose metabolism in the sulfonylurea receptor 1 knockout rat model
Zhou, X., Xu, C., Zou, Z., Shen, X., Xie, T., Zhang, R., Liao, L., & Dong, J. (2019) · Molecular Medicine · doi:10.1186/s10020-018-0067-9 · Cited by 9
Preserving insulin secretion in Type 2 diabetes mellitus
Tibaldi, J. M. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.2.147 · Cited by 11
Bunyatyan, N. D., Бухтиярова, И. П., Дроговоз, С. М., Кононенко, А. В., Olefir, Y. V., Prokofiev, A. B., Анатольевна, П. И., & Goryachev, D. V. (2017) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-017-1621-4 · Cited by 8
KAZDA, C. M., Gallwitz, B., Simó, R., Guzmán, J. R., Kraus, P., Nicolay, C., Rose, L., & Schernthaner, G. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01091.x · Cited by 8
Incretin-Based Therapy for Type 2 Diabetes Mellitus: Pancreatic and Extrapancreatic Effects
Hartman, I., Rojas, E., & Rodríguez-Molina, D. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f27d · Cited by 9
“Loss of this early-phase insulin secretion is postulated to be prominent feature of T2D that causes postprandial hyperglycemia.(9,11)”
BackgroundUhles, S., Wang, H., Benardeau, A. M., Prummer, M., Brecheisen, M., Sewing, S., Tobalina, L., Bosco, D., Wollheim, C. B., Migliorini, C., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01352.x · Cited by 9
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Diamant, M., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2017) · Diabetic Medicine · doi:10.1111/dme.13160 · Cited by 7
Musale, V., Guilhaudis, L., Abdel‐Wahab, Y. H. A., Flatt, P. R., & Conlon, J. M. (2018) · Biochimie · doi:10.1016/j.biochi.2018.09.008 · Cited by 7
Dipeptidyl Peptidase (DPP)-IV Inhibitor: A Novel Class of Oral Anti-hyperglycemic Agents
Ng, V. W., & Kong, A. P. S. (2007) · Cited by 7
Therapy targeting β-cell survival and function in type 2 diabetes mellitus
Pørksen, N. K. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.06.014 · Cited by 8
The role of incretin on diabetes mellitus.
Sanusi, H. D. (2009) · PubMed · Cited by 8
Association of Exenatide With Liver Enzymes in Patients With Type 2 Diabetes
Bulchandani, D. G., Nachnani, J. S., Eaton, C., & Hamburg, M. S. (2009) · The Endocrinologist · doi:10.1097/ten.0b013e3181a48938 · Cited by 6
Traitement du diabète de type 2 : l’exénatide à libération prolongée
Guerci, B., & Sauvanet, J.-P. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70734-5 · Cited by 6
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Diamant, M., den Bos, I. C. P.-V., van Raalte, D. H., & Cahen, D. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12612 · Cited by 7
“This schedule was chosen because it yields exenatide plasma levels within the therapeutic range (130–150 pg/ml), has similar pharmacokinetics to subcutaneous injection, and is well tolerated [26,27].”
BackgroundMiyachi, A., Kondo, F., Kurita, M., Tsuji, K., & Harada, K. (2015) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2014.10.029 · Cited by 8
Physiological and biochemical measurements before, during and after pregnancy of healthy rats
Corvino, S. B., Volpato, G. T., MACEDO, N. C. D., Sinzato, Y. K., Rudge, M. V. C., & Damasceno, D. C. (2015) · Acta Cirúrgica Brasileira · doi:10.1590/s0102-865020150100000003 · Cited by 6
Green, J. B., & Feinglos, M. N. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0060-0 · Cited by 6
“Administration of exenatide to individuals with type 2 diabetes augments both first- and second-phase insulin secretion, and may restore first-phase insulin secretion in individuals in whom it was previously absent [15, 16 ].”
BackgroundSpecial Features: Incretin-based therapies in type 2 diabetes mellitus
Cw, C., Jm, E., Chia, C. W., Egan, J. M., correspondence, A., & Egan, J. M. (2014) · Cited by 6
Supramolecular oral delivery technologies for polypeptide-based drugs
Chen, J., Liu, T., Wang, M., Lü, B., Bai, D., Shang, J., Chen, Y., & Zhang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.045 · Cited by 5
Is there U-turn from Insulin Back to Pills in Diabetes?
Ertek, S., & Çetinkalp, Ş. (2014) · Current Vascular Pharmacology · doi:10.2174/15701611113119990122 · Cited by 5
GAD‐65 antibodies in a case of HNF1A‐Maturity‐Onset Diabetes of the Young: Double diabetes?
Sjöholm, Å. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4151 · Cited by 5
Webb, D. M., Wintle, M. E., & Malone, J. K. (2006) · Drug Development Research · doi:10.1002/ddr.20115 · Cited by 5
“Another important and immediate effect on the beta cell is the restoration of first-phase insulin secretion [Fehse et al., 2005].”
BackgroundLe, Y., Yang, K., Yang, J., Fu, W., Xiao, W., Wei, R., & Hong, T. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01310-3 · Cited by 4
“control and reduces body weight in patients with T2DM [17, 18].”
BackgroundQuan, H., Gao, Y., Zhang, H., Fang, T., Chen, D., Lv, Z., & Chen, Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2538 · Cited by 5
“Exenatide, a GLP-1 receptor agonist that exhibits sustained activity, has potential for the treatment of T2DM due to its ability to enhance insulin secretion and increase β -cell mass (7-9).”
Clinical Management Strategies for Type 2 Diabetes
Cefalu, W. T., & Urquhart, S. (2007) · JAAPA · doi:10.1097/01720610-200712000-00002 · Cited by 5
Raghavan, V. A., & Garber, A. J. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_7 · Cited by 5
Patterns of Insulin Secretion During First-Phase Insulin Secretion in Normal Chinese Adults
Yuan, T., Song, S., Zhao, T., Duo, Y., Wang, S., Gao, J., Liu, S., Dong, Y., Li, R., Fu, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738427 · Cited by 5
“It seems that the restoration of FPIS and improvement of plasma glucose in T2DM is interacted, which has thus prompted many studies into its regulation (4, 5).”
BackgroundTreatment Strategies for Type 2 Diabetes Based on Incretin Action
Gallwitz, B., & Nauck, M. A. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-13 · Cited by 5
Self-citationGrandy, S., & Shaunik, A. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000643 · Cited by 6
“investigated insulin secretory patterns and the effects of exenatide on insulin secretion and found that in patients with T2D (N=13), the first-phase insulin response was reduced compared with healthy control subjects (N=12) [23].”
ResultThe Rationale for Prandial Glycemic Control in Diabetes Mellitus
Perkins, J. M., & Davis, S. N. (2007) · Insulin · doi:10.1016/s1557-0843(07)80016-9 · Cited by 4
Exenatide: incretin therapy for patients with Type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.6.671 · Cited by 5
How do different GLP-1 mimetics differ in their actions?
Choukem, S. P., & Gautier, J. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0007-x · Cited by 4
“Stimulation of beta-cell function* +++ [ 33 ] +++ [34,35] + [42,43,46] Stimulation of insulin sensitivity Yes [26] No [34] Yes [46]”
BackgroundCirincione, B. B., LaCreta, F. P., Sager, P. T., & Mager, D. E. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.882 · Cited by 3
Levine, J. A., Kaihara, K. A., Layden, B. T., & Wicksteed, B. L. (2016) · Islets · doi:10.1080/19382014.2016.1198457 · Cited by 3
The Role of Incretins in Insulin Secretion
Schroeder, B. E., & Kolterman, O. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_4 · Cited by 3
[Exenatide trials for the treatment of type 2 diabetes].
Landó, L. F., & CASELLINI, C. M. (2009) · PubMed · Cited by 6
Las incretinas como nuevas dianas terapéuticas de la diabetes tipo 2
Puig‐Domingo, M., & Reviriego, J. (2007) · Revista Clínica Española · doi:10.1157/13107949 · Cited by 4
de la Peña, A., Loghin, C., Cui, X., Zhang, X., Kapitza, C., & Kelly, R. P. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12847 · Cited by 4
“Furthermore, administration of GLP-1 (7-36) amide or GLP-1 receptor agonists in T2DM has been shown to restore first- and second-phase Received: 13 September 2016 Revised: 29 November 2016 Accepted: 6 December 2016”
BackgroundInfluentialManagement of type 2 diabetes: the GLP‐1 pathway
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2008) · Future Prescriber · doi:10.1002/fps.39 · Cited by 3
Non-Insulin Treatments for Diabetes
Angueira-Serrano, E. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318235f2cb · Cited by 3
“In a study comparing exenatide with placebo and their effects on insulin secretion in patients with type 2 diabetes after an intravenous glucose bolus, exenatide was able to increase insulin secretion to levels similar to those of normal controls.(18) In a study evaluating the effect of exenatide on postprandial gluco…”
ResultLongacting exenatide in diabetes: DURATION-3
Misra, A., & Joshi, S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60836-7 · Cited by 3
Ravasio, R. (2008) · Giornale Italiano di Health Technology Assessment · doi:10.1007/bf03320710 · Cited by 3
Assessment of Islet Alpha- and Beta-Cell Function
Madsbad, S., & Holst, J. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_2 · Cited by 4
Self-citationBode, B. W., & Amin, A. (2009) · Hospital Practice · doi:10.3810/hp.2009.12.249 · Cited by 2
Vlasakakis, G., Johnson, S. L., Lin, J., Yao, X., Gruenloh, C. J., Chism, J. P., & Nunez, D. J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0222-4 · Cited by 2
“Their pharmacological actions include a dose-dependent stimulation of insulin secretion, suppression of pancreatic glucagon release, a reduction of appetite and food intake, and a slowing of gastric emptying [4, 5], as well as promotion of b-cell proliferation and islet neogenesis, both in vitro [6] and in vivo [7], a…”
BackgroundOdegard, P. S., & DeSantis, A. J. (2009) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s4444 · Cited by 3
“Beta cell function Research on exenatide suggests a beneficial effect on first and second phase insulin secretion.(44) Two recent studies have explored this potential using measurement and simulation of beta cell function.”
Significance of Organ Crosstalk in Insulin Resistance and Type 2 Diabetes
Bhatt, S., & Kulkarni, R. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-415784-2.00017-8 · Cited by 3
Non‐Insulin Parenteral Therapies
Holst, J. J., Madsbad, S., & Schmitz, O. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch30 · Cited by 4
Self-citationIncretin-Based Therapies for Type 2 Diabetes: Clinical Utility
Ratner, R. E. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)70005-1 · Cited by 3
Jamaludin, U. K. (2013) · UMP Institutional Repository (Universiti Malaysia Pahang) · doi:10.26021/3488 · Cited by 3
“This is supported by the literatures (Fehse et al. 2005; Garvey et al. 1985; Luzi and DeFronzo 1989).”
Seo, D. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.85.2017.tde-23032017-153731 · Cited by 2
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
“exenatide acutely improved first- and second-phase insulin secretion in patients with T2DM [41].”
BackgroundChirurgie bariatrique et insulinosécrétion : Où en est-on ?
Andréelli, F. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30199-1 · Cited by 1
Behary, P., Godsland, I. F., & Baynes, K. (2014) · Practical Diabetes · doi:10.1002/pdi.1867 · Cited by 2
Incretins: new targets for the prevention of diabetes and obesity
Neff, K., & le Roux, C. W. (2013) · Clinical Lipidology · doi:10.2217/clp.12.80 · Cited by 1
Molecular Basis of cAMP Signaling in Pancreatic Beta Cells
Holz, G. G., Chepurny, O. G., Leech, C. A., Song, W., & Hussain, M. A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_25-3 · Cited by 1
Pharmacological Treatments for Type 2 Diabetes
Pontarolo, R., Sanches, A. C. C., Wiens, A., Borba, H. H. L., Lenzi, L., & Penteado, S. T. D. S. (2013) · InTech eBooks · doi:10.5772/56456 · Cited by 4
Censani, M., Chin, V. L., & Fennoy, I. (2015) · Journal of Obesity and Weight-loss Medication · doi:10.23937/2572-4010.1510004 · Cited by 3
“Adult longitudinal studies have documented normalized blood glucose, improved HbA1c, and weight loss in patients with type 2 diabetes [7-9].”
Management of type 2 diabetes: the role of incretin mimetics
Holcombe, J. H., Kim, D. D. H., Stonehouse, A. H., & Kendall, D. M. (2006) · Drug Development Research · doi:10.1002/ddr.20120 · Cited by 2
Self-citationHow incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes
(2010) · The Internet Journal of Academic Physician Assistants · doi:10.5580/172c · Cited by 1
“cell function in vitro by reducing beta cell apoptosis (39,40), and in vivo by enhancing first and second-phase insulin response to a glucose challenge (41), both of which are”
BackgroundGemeinsamkeiten und Unterschiede inkretinbasierter Therapien
Gallwitz, B. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0696-x · Cited by 1
TRANSLATIONAL MEDICINE AND ITS IMPACT ON DIABETES DRUG DEVELOPMENT
Calle, R. A., & Taylor, A. E. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976087.004
Diabetes update 2006: urgency for new approaches.
Gavin, J. R. (2007) · PubMed
Penfornis, A., & Sauvanet, J.-P. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70891-0
Fleury‐Milfort, E. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00454.x · Cited by 1
“Both exenatide and liraglutide enhance the first and second phases of the prandial insulin response (Fehse et al., 2005; Vilsbøll et al., 2008), and reductions in both fasting plasma glucose (FPG) and peak postprandial glucose (PPG) have been seen in clinical studies of liraglutide (Monnier, Lapinski, & Colette, 2003;…”
BackgroundL’exénatide Quoi ? Comment ? Pour qui ?
Choukem, S. P., & Gautier, J. (2007) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(07)74148-2
Krentz, A. J., Heinemann, L., & Hompesch, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_2
Andreani, T., Souto, E. B., Silva, A. M., & Lopes, C. M. (2009) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
La terapia del diabete mellito tipo 2 basata sulle incretine
Prato, S. D., Sesti, G., Bonora, E., Bosi, E., Consoli, A., Cucinotti, D., Ghirlanda, G., Giorgino, F., Lauro, D., Marchetti, P., et al. (2008) · CINECA IRIS Institutial research information system (University of Pisa)
The Effects of Incretin Mimetics on Islet Cell Function in Type 2 Diabetes
Marchetti, P., & Boggi, U. (2008) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2008.04.02.50
Can drugs used in type 2 diabetes therapy induce acute pancreatitis?
Borowik, A., Hrycek, A., Chudek, J. T., & Olszanecka‐Glinianowicz, M. (2011) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.964936
“Syntetyczne analogi GLP-1 nasilają stymulowane glukozą wydzielanie insuliny, przywracając fizjologiczny rytm zarówno pierwszej, jak i drugiej fazy jej sekrecji, ponadto hamują sekrecję glukagonu [15].”
BackgroundImportance of glycemic control.
Shahady, E. J. (2011) · PubMed
Exenatide — A Novel Treatment to Manage Type 2 Diabetes Mellitus
Puig‐Domingo, M., & Ríos, A. G. (2007) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2007.00.01.23 · Cited by 1
and unchanged glucose effectiveness in patients with type 2 diabetes
Martinussen, C., Bojsen-Møller, K. N., Dirksen, C., Jørgensen, N. B., Kristiansen, V. B., Holst, J. J., & Madsbad, S. (2015)
Self-citationSimulation Model of Insulin Granule Dynamics in Pancreatic Beta Cell
Matsumoto, T., Tabata, N., Tamaki, H., Shibasaki, T., Seino, S., Sunaga, Y., Yokota, H., & Fukushima, M. (2015) · IEEJ Transactions on Electronics Information and Systems · doi:10.1541/ieejeiss.135.963
Metabolic effects of dipeptyl peptidase 4 inhibitor in type 2 diabetes
Macauley, M. (2016)
Incretin‐Based Therapy for the Management of Type 2 Diabetes
Gonzales, K., & Vella, A. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch12
Methodologies of Pharmacodynamic Assessment
Pfeiffer, C., & Ruus, P. (2010) · Springer eBooks · doi:10.1007/978-3-540-89891-7_28
Wriedt, E. B., Kielgast, U. L., Svane, M. S., Møller, S., & Madsbad, S. (2024) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2024.2306537
“The intravenous glucose tolerance test is established as a test for the beta-cell function in patients with type 1 and 2 diabetes and to examine the insulin response following various pharmacological treatments [26,29,30].”
BackgroundSuplotova, L. A., & Tilkiyan, A. S. (2025) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2025-14-2-44-52
Birth of a Microdomain: Can Glucose Act as a Metabolic Switch?
Pallavi, A., & Gandasi, N. R. (2025) · DNA and Cell Biology · doi:10.1177/10445498251391706
“This in turn leads to reduced glucose uptake, leading to 50% reduced insulin secretion, which can be equated to 525 – 4000 pg/mL (Fehse et al., 2005; Gandasi et al., 2018).”
Silfvergren, O., Rigal, S., Schimek, K. M. S., Simonsson, C., Kanebratt, K. P., Forschler, F., Yesildag, B., Marx, U., Vilén, L., Gennemark, P., et al. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107648 · Cited by 2
Additional file 1 of GRK2 regulates GLP-1R-mediated early phase insulin secretion in vivo
Arcones, A. C., Vila‐Bedmar, R., Mirasierra, M., Cruces‐Sande, M., Vallejo, M., Jones, B. J., Tomás, A., Mayor, F., & Murga, C. (2021) · Figshare · doi:10.6084/m9.figshare.14157718
Silfvergren, O., Rigal, S., Schimek, K. M. S., Simonsson, C., Kanebratt, K. P., Forschler, F., Yesildag, B., Marx, U., Vilén, L., Gennemark, P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.25.714139 · Cited by 3
“Therefore, the effect of exenatide is implemented as acting solely on glucose-dependent insulin secretion in the mathematical model ( Supplementary Note S1 ), consistent with clinical observations (28) .”
Restaurer la fonction bêta pancréatique de la souris leptine déficiente par la chirurgie bariatrique
Amouyal, C. (2019) · theses.fr (ABES) · doi:10.70675/57e90c8dz951az4b06z95cdzc78f34db6015
Varra, F., Theodosis‐Nobelos, P., Varra, V., & Varras, M. N. (2026) · Medicina · doi:10.3390/medicina62081445
Horiuchi, Y. (2018) · Institutional Repositories DataBase (IRDB) · doi:10.15083/00077848
Metadata
- Authors
- Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Eli Lilly (United States) (US)
- University of Copenhagen (DK)
- Corresponding author
- Nauck, Michael A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-11
- Volume
- 90
- Issue
- 11
- Pages
- 5991-5997
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2039296612
- Cited by
- 297
- References
- 55
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 7 · 2016: 15 · 2015: 24 · 2014: 22 · 2013: 21 · 2012: 9
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, type 2 diabetes, first-phase insulin secretion, second-phase insulin secretion, incretin mimetics, glucose-dependent insulin secretion, insulin secretion rate, C-peptide, glucagon, insulin resistance, metformin, acarbose, glucoregulation, GLP-1 receptor
- MeSH terms
- Exenatide, Insulin Secretion, Adult, Diabetes Mellitus, Type 2, Female, Glucose, Humans, Insulin, Male, Middle Aged, Peptides, Venoms, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.